SCIEX Announces Exclusive Co-Marketing Agreement with Pressure
BioSciences, Inc. to Improve Protein Quantitation in Complex
Samples
SCIEX and Pressure BioSciences to Offer Complete Solution for
Next- Generation Proteomics, to Increase the Reproducibility and
Depth of Proteomic Analysis
Framingham, MA -- January 12, 2016 -- InvestorsHub NewsWire --
SCIEX, a global leader in life science analytical
technologies, today announced an exclusive co-marketing agreement
with Pressure BioSciences, Inc. (PBI) (OTCQB:
PBIO), a worldwide leader in the development and sale of high
pressure-based sample preparation systems to the life sciences
research market. This relationship will uniquely position SCIEX to
address a major challenge in complex sample preparation by
marketing a complete solution to increase the depth, breadth, and
reproducibility of protein extraction, digestion and quantitation
in all tissue types, including challenging samples like tumors.
Under this Agreement, PBI and SCIEX will promote pressure cycling
technology (PCT) sample preparation systems such as PCT-HD (PCT
High Definition) with SWATH Acquisition based next-generation
proteomics, TripleTOF Systems, QTRAP Systems, and Triple Quad Systems. This focus
on improved sample preparation, a crucial step performed in
research laboratories worldwide, will enable scientists to extract
more proteins reproducibly from complex sample types, potentially
yielding superior biological insights and discoveries.
PCT Sample Preparation Systems enable faster, automated, less
cumbersome, and higher quality extraction, homogenization, and
digestion of proteins from tissue samples by utilizing controlled
cycles of pressure to break apart the samples. This results in
faster and improved sample processing, and a higher quality of
results. When combined with SWATH Acquisition, the "missing data
problem" is vastly improved, as PCT-based sample preparation
increases the reproducibility and quantitative accuracy of
label-free proteomics, greatly outperforming classic shotgun
methods that measure an incomplete set of proteins that are
difficult to reproduce. Thus, SWATH Acquisition with PCT sample
preparation makes reproducible proteome research feasible across
the enormous diversity of complex biological samples.
PCT-HD was developed by PBI scientists and engineers in
collaboration with Professor Ruedi Aebersold and Dr. Tiannan Guo of
the Institute of Molecular Systems Biology, ETH Zurich, and the
University of Zurich, in Switzerland. Drs. Aebersold and Guo
combined PCT-HD sample preparation with SCIEXs SWATH-Mass
Spectrometry naming the resulting method PCT-SWATH. This unique
protocol can yield proteome analysis results within 12 hours from
the start of processing tissue, much faster than current
methods.
By addressing the significant challenges inherent in complex
sample preparation to reproducibly analyze thousands of proteins in
hundreds of samples, PCT-SWATH accelerates proteomics research in
biologically and clinically-relevant contexts, states Dr.
Aebersold. This should increase the chance for biomarker discovery,
potentially leading to significant improvements in healthcare,
including personalized medicine.
Advancing precision medicine through the ability to reproducibly
quantitate thousands of proteins in large clinical sample cohorts
is of the utmost importance to both academic and clinical research
labs, said Mark Cafazzo, Director of Academic and Clinical Research
Business at SCIEX. The combination of PCT sample preparation with
SWATH Acquisition delivers a powerful method to industrialize
proteomics research, including the most complex and challenging
biospecimens. By partnering with PBI and adding the PCT technology
to SCIEX next-generation proteomic solutions, we help scientists
address the sample preparation challenges they face every day,
especially when working with difficult tissue samples.
Mr. Cafazzo continued: The net result is more comprehensive
protein quantitation from complex samples, increased productivity
and higher quality results. This is an exciting step forward for
the field of proteomics, one that offers the potential to make a
great and lasting impact on the quality of human life.
Bringing the PCT platform into the research laboratory enables
scientists to efficiently and reproducibly break apart tissue
samples and greatly accelerate their processing, said Richard T.
Schumacher, President and CEO of PBI. By combining these methods
with SCIEXs expertise and successful history in mass spectrometry
system solutions, clinical researchers will be equipped to make
major leaps forward in proteomic analysis, over the current
limitations of traditional methods.
While mass spectrometry (MS) is already the gold standard tool
for proteomic analysis, advanced sample preparation techniques like
the PCT platform, which decrease starting material requirements
while increasing the quality of results, will continue to expand
the use of mass spectrometry in clinical research. This agreement
between SCIEX and PBI is expected to significantly expand the
footprint of MS-based quantitation workflows in clinical research
settings worldwide.
Learn more about SCIEX Proteomics Solutions and Pressure
BioSciences PCT-SWATH
About SCIEX
SCIEX helps to improve the world we live in by enabling
scientists and laboratory analysts to find answers to the complex
analytical challenges they face. The company's global leadership
and world-class service and support in the capillary
electrophoresis and liquid chromatography-mass spectrometry
industry have made it a trusted partner to thousands of the
scientists and lab analysts worldwide who are focused on basic
research, drug discovery and development, food and environmental
testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by
listening to and understanding the ever-evolving needs of its
customers to develop reliable, sensitive and intuitive solutions
that continue to redefine what is achievable in routine and complex
analysis. For more information, please visit sciex.com.
SCIEX social: Twitter: @SCIEXnews, LinkedIn
and Facebook.
For Research Use Only. Not for use in diagnostic procedures.
AB Sciex is operating as SCIEX.
2015 AB Sciex. The trademarks mentioned herein are the property
of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex is
being used under license.
RUO-MKT-12-3185-A
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB:
PBIO) develops, markets, and sells proprietary laboratory
instrumentation and associated consumables to the estimated $6
billion life sciences sample preparation market. Our products
are based on the unique properties of both constant (i.e., static)
and alternating (i.e., pressure cycling technology, or PCT)
hydrostatic pressure. PCT is a patented enabling technology
platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions. To date, we have installed over
250 PCT systems in approximately 160 sites worldwide. There are
over 100 publications citing the advantages of the PCT platform
over competitive methods, many from key opinion leaders. Our
primary application development and sales efforts are in the
biomarker discovery and forensics areas. Customers also use our
products in other areas, such as drug discovery & design,
bio-therapeutics characterization, soil & plant biology,
vaccine development, histology, and counter-bioterror applications.
Contact Information
Stacey Sicurella, Manager Global Public Relations and Brand,
SCIEX
Stacey.sicurella@sciex.com
508-688-7958
Editorial follow-up
Patrick Farrell, Sniper Public Relations on Behalf of SCIEX
pfarrell@sniperpr.com
603-420-8828